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The P7C3 class of neuroprotective aminopropyl car-
bazoles has been shown to block neuronal cell death
in models of neurodegeneration. We now show
that P7C3 molecules additionally preserve axonal
integrity after injury, before neuronal cell death oc-
curs, in a rodent model of blast-mediated traumatic
brain injury (TBI). This protective quality may be
linked to the ability of P7C3 molecules to activate
nicotinamide phosphoribosyltransferase, the rate-
limiting enzyme in nicotinamide adenine dinucleotide
salvage. Initiation of daily treatment with our recently
reported lead agent, P7C3-S243, 1 day after blast-
mediated TBI blocks axonal degeneration and pre-
serves normal synaptic activity, learning and mem-
ory, and motor coordination in mice. We additionally
report persistent neurologic deficits and acquisition
of an anxiety-like phenotype in untreated animals
8 months after blast exposure. Optimized variants
of P7C3 thus offer hope for identifying neuroprotec-
tive agents for conditions involving axonal damage,
neuronal cell death, or both, such as occurs in TBI.
INTRODUCTION
Traumatic brain injury (TBI) has emerged as the signature injury
of military conflict, estimated to affect 20% of the 2.3 million
servicemen and women deployed since 2001. Blast exposureCell Refrom explosive devices affects soldiers and civilians around
the globe, placing them at increased risk for TBI associated
with long-term neurologic complications, including cognitive
and motor decline, acquisition of psychiatric symptoms, and
neuropathological features similar to Alzheimer’s disease
(Hoge et al., 2008; Wolf et al., 2009; Shively et al., 2012; Gold-
stein et al., 2012). Whereas the mechanisms of injury from
exposure to the blast-generated shockwave are incompletely
understood, the associated sheer forces are known to lead to
widespread, diffuse, and progressive axonal injury (Nakagawa
et al., 2011; Magnuson et al., 2012). Unfortunately, just as
there are currently no pharmacologic agents that arrest neuron
cell death in any of the wide spectrum of neurodegenerative
diseases, such as Alzheimer’s disease, Parkinson’s disease,
or amyotrophic lateral sclerosis, there are also currently no
treatment options for patients with TBI beyond supportive
and rehabilitative care.
The lack of pharmacologic strategies to block neuron cell
death relates to the failure of target-directed drug discovery
programs to develop neuroprotective therapeutics. Phenotypic
screening, by contrast, offers the opportunity for discovery of
new compounds with a desired biologic effect without bias con-
cerning mechanism (Pieper et al., 2014). With this in mind, we
previously implemented an in vivo phenotypic screen in living
mice to identify small drug-like molecules that safely increased
the net magnitude of postnatal hippocampal neurogenesis. We
designed the screen to capture agents that would either enhance
proliferation or block death of newborn hippocampal neural pre-
cursor cells (Pieper et al., 2010) and identified an aminopropyl
carbazole, named ‘‘P7C3,’’ that was fortuitously endowed with
favorable pharmacokinetic properties (Pieper et al., 2010). Itports 8, 1731–1740, September 25, 2014 ª2014 The Authors 1731
was subsequently demonstrated that P7C3 achieved its pro-
neurogenic effect by virtue of blocking death of neural precursor
cells. We later demonstrated additional protective benefit of
P7C3 molecules, specifically the highly active analog P7C3-
A20, in blocking neuronal cell death and improving neurologic
outcomes in a variety of rodent models of neurodegenerative
disease and injury, including those involving death of mature
neurons in other regions of the CNS (MacMillan et al., 2011; Nai-
doo et al., 2013;Walker et al., 2014; De Jesu´s-Corte´s et al., 2012;
Tesla et al., 2012; Blaya et al., 2014).
Recently, we reported the synthesis and characterization of
an optimized member of the P7C3 series, ()-P7C3-S243,
which exhibits improved polarity and lacks the aniline moiety
present in other members of the P7C3 series. This analog is
readily available as a single enantiomer with selective neuro-
protective activity (Naidoo et al., 2014). Because blast expo-
sure in rodents results in a phenotype that recapitulates the
consequences of blast-mediated TBI experienced by humans
(Goldstein et al., 2012; Mohan et al., 2013), this animal model
is suitable for evaluating the efficacy of neuroprotective
agents. Here, we describe protective efficacy of P7C3-S243
in the mouse model of blast-induced TBI, which has also led
to the discovery of a protective quality of the P7C3-class—
the ability to block axonal degeneration preceding neuronal
cell death.
RESULTS
To test the neuroprotective efficacy of P7C3-A20 and P7C3-
S243, we employed a model of blast-induced TBI in which the
blast wave is propagated following rupture of a mylar membrane
(Mohan et al., 2013). Briefly, anesthetized mice are placed in an
enclosed blast chamber constructed from an air tank partitioned
into two sides. A sealed mylar membrane covers a small port be-
tween the two halves of the tank. When the pressure is increased
in the side without the mouse, the membrane ruptures at z22
kilopascal (kPa), generating a blast wave that travels through
the mouse’s head. The head of the mouse is untethered and
located in a padded holder, whereas the body is shielded from
the blast by a metal tube. As previously reported (Mohan et al.,
2013), the intensity of the blast wave in our system is 149.8 ±
2.09 kPa, and the duration of the total pressure (blast wave +
wind gust) isz10–15 ms.
We first evaluated hippocampal-dependent memory in the
Barnes maze task after blast injury, with immediate administra-
tion of test compounds. The Barnes maze consists of a circular
table with holes equally spaced around the perimeter. One of
these holes contains an escape cup, such that the mouse can
enter the hole and hide in the cup to avoid exposure on the table.
Testing in the Barnes maze was initiated 7 days after blast injury.
To begin, mice underwent 4 days of training, during which time
they were allowed to find and enter the escape hole and rest in
the protective cup. By the 4th day of training, mice typically learn
how to rapidly locate the escape hole, based on visual cues
permanently positioned around the table throughout training. Af-
ter 4 days of training, the cup is removed and the ability of the
mouse to remember where the cup was previously located is as-
sessed in the ‘‘probe test’’. Memory is reflected by measuring1732 Cell Reports 8, 1731–1740, September 25, 2014 ª2014 The Authe amount of time the mouse spends in the area around where
the cup was previously located. Sham-injured animals that were
intraperitoneally administered daily vehicle, P7C3-A20, or P7C3-
S243 spent 55%–60% of their time in the quadrant that con-
tained the escape hole, known as the ‘‘escape quadrant,’’ during
the probe test (Figure S1A), indicating that normal memory is not
affected by P7C3 compounds in this task. By contrast, blast-
injured animals administered vehicle were notably impaired,
spending onlyz25% of their time in the escape quadrant, which
would be expected by chance alone (Figure S1A). Daily treat-
ment with P7C3-A20 or P7C3-S243 immediately after injury,
however, restored the time spent in the escape quadrant to
normal levels seen in uninjured mice (Figure S1A).
Delayed Initiation of Treatment with P7C3-S243
Preserves Learning and Memory after
Blast-Mediated TBI
On the basis of the promising results seen with administration
of P7C3 molecules immediately after injury, we sought to deter-
mine whether P7C3-S243 could offer protective efficacy when
treatment was initiated later. Because TBI can disrupt the
blood-brain barrier (BBB), we first examined BBB integrity
over time by means of the Evans blue assay. Evans blue is an
azo dye with tight affinity for albumin, such that in serum virtu-
ally all Evans blue is albumin bound. Normally, serum albumin
cannot cross the BBB. However, when the BBB is compro-
mised, albumin and its bound Evans blue can enter the CNS.
The magnitude of Evans blue accumulation in the brain can
then be spectrophotometrically determined in order to monitor
disruption of the BBB (Uyama et al., 1988; Hawkins and Egle-
ton, 2006). With this technique, we observed significant disrup-
tion of the BBB 6 hr after blast injury, with integrity of the BBB
recovering to normal 18 hr later (Figure S1B). BBB integrity re-
mained intact 102 hr after injury, and 3 days of daily treatment
with P7C3-S243 did not compromise BBB integrity in sham-
injured mice.
We next tested whether P7C3-S243 could preserve function
when treatment was initiated 24 hr after blast injury, when the
BBB was intact. A schematic of this experimental design is illus-
trated in Figure S1C, and we have previously reported that
P7C3-S243 readily enters the brains of mice with intact BBBs
(Naidoo et al., 2014). We reasoned that this time point for starting
treatment represented an important milestone, as most patients
would be expected to access treatment within 24 hr of their
injury. Every group consisted of 25 male C57/Bl6 wild-type
mice, aged 12–14 weeks, and data were collected and analyzed
in an automated manner blind to treatment group. The most
stringent measure of performance in the Barnes maze probe
test is percent time in the escape area, defined as a 5 cm radius
surrounding the escape hole. Sham-injured animals treated with
vehicle or 10 mg/kg/day P7C3-S243 spentz39%–43% of their
time in the escape area, as opposed to only z15% for injured
animals treated with vehicle (Figure 1A). Daily treatment with
P7C3-S243 initiated 24 hr after injury dose-dependently pre-
served performance in this measure, with 3, 10, and 30 mg/kg/
day doses showing complete protection and 1 mg/kg/day par-
tial, though not statistically significant, protection (Figure 1A).
Administration of the active enantiomer ()-P7C3-S243 atthors
Figure 1. P7C3-S243 Preserves Memory after Blast-Mediated TBI
(A) Daily i.p. administration of P7C3-S243 for 11 days in divided daily doses for
the total amount indicated dose-dependently preservedmemory in the Barnes
maze probe test in blast-injured mice, as measured by the most stringent
measure of percent time in escape area (5 cm radius around the escape hole).
Treatment with an intermediate dose (3 mg/kg/day) of the active ()-P7C3-
S243 enantiomer preserved normal performance to the level displayed by
sham-injured mice. By contrast, mice treated with the same dose of the less-
active (+)-P7C3-S243 enantiomer showed the same deficit as injuredmice that
were treated with vehicle.
(B) Daily administration of P7C3-S243 was initiated at later time periods after
injury to define the window of therapeutic efficacy. Whereas both 3 and 30mg/
kg/day doses preserved normal function when treatment was initiated 24 hr
after injury, only the 30 mg/kg/day dose was efficacious when treatment was
initiated at 36 hr. When treatment was initiated 48 hr after injury, no protective
efficacy was noted at any dose.
(C) Oral administration of the highly active ()-P7C3-S243 enantiomer pre-
served normal hippocampal-dependent memory at 3, 10, and 30 mg/kg/day
doses. Every group shown consisted of 25 male C57/Bl6 mice, aged 12–
14 weeks, and data were collected and scored in an automated manner blind
to treatment group. Data are represented as mean ± SEM. Significance was
determined by two-way ANOVA with Bonferroni post hoc analysis. *p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001 compared to blast-injured animals
treated with vehicle.
See also Figures S1 and S2.3 mg/kg/day showed complete protection, whereas the same
dose of the less-active enantiomer, (+)-P7C3-S243, showed no
efficacy (Figure 1A).
Next, we sought to define the time window of treatment effi-
cacy by initiating daily intraperitoneal (i.p.) administration of
P7C3-S243 at later points after injury. Whereas both 3 and
30 mg/kg/day doses preserved normal function when treatment
was initiated 24 hr after injury, only the 30 mg/kg/day dose was
partially efficacious when initiated 36 hr after injury (Figure 1B).
When initiated 48 hr after injury, no protective efficacy wasCell Renoted at any dose (Figure 1B). Thus, acute memory deficits after
blast-mediated TBI can be effectively mitigated when treatment
with P7C3-S243 is initiated within 36 hr. Finally, we tested
whether oral administration of the highly active ()-P7C3-
S243 enantiomer could achieve protective effect. Indeed, initia-
tion of daily oral administration of ()-P7C3-S243 at 24 hr after
injury preserved memory at 3, 10, and 30 mg/kg/day doses
(Figure 1C).
In addition to measuring time spent in the 5 cm radius around
the escape hole in the probe test, we also tested other com-
monly used measures of memory. Specifically, we determined
the percent of nose pokes into the correct hole, defined as
‘‘target entry,’’ and the percent of time spent in the quadrant
of the maze containing the escape hole, defined as ‘‘percent
quadrant time’’. Monitoring of target entry in the treatment
groups showed the same protective effects as with the escape
area measure (Figures S2A–S2C). Similar findings were also
obtained with the metric of percent quadrant time, with the
exception that 3 mg/kg/day of the less active (+)-P7C3-S243
enantiomer achieved some measure of protective efficacy at
the margin of statistical significance (Figures S2D–S2F). This
modest effect indicates that low-level activity may reside in
(+)-P7C3-S243.
As controls in the Barnes maze, we examined the ability of
animals to physically participate in the task, as well as to learn
the task over the 4-day training period. Physical participation
was defined as speed and distance traveled, and none of the
groups differed significantly in these measures (Figures S2G–
S2L). Learning was assessed as the percent latency to escape,
defined as the percentage of time the mouse took to enter
the escape hole on day 4 out of the time originally required on
day 1. All animals were able to learn, though mice subjected to
blast-mediated TBI and then treated with vehicle, 0.3 mg/kg/
day P7C3-S243, or 3 mg/kg/day of the less-active enantiomer
(+)-P7C3-S243 learned significantly worse than sham-injury
mice (Figure S2M). When treatment with 1, 3, 10, or 30 mg/kg/
day P7C3-S243 or 3 mg/kg/day ()-P7C3-S243 was initiated
24 hr after injury, however, mice learned the task as well as
sham-injury mice (Figure S2M). Notably, the 1 mg/kg/day dose
failed to improve memory in the probe test (Figure 1A) yet still
facilitated learning during the training period.
Initiation of administration of 3 and 30 mg/kg/day doses of
P7C3-S243 at 36 hr after injury improved learning (Figure S2N),
even though the 3 mg/kg/day dose did not improve memory in
the probe test (Figure 1B). Similarly, 30 mg/kg/day P7C3-S243
restored normal learning when treatment was initiated 48 hr after
injury (Figure S7C), despite having no effect on memory in the
probe test (Figure 1C). Finally, oral administration of 1 mg/kg/
day ()-P7C3-S243, which did not preservememory in the probe
test (Figure 1C), also restored normal learning (Figure S2O).
Taken together, it can be concluded that treatment with P7C3-
S243 mitigates acute neurocognitive deficits after blast-medi-
ated TBI and improves learning during the training period of
the Barnes maze at doses lower than those required for the
more-challenging task of preserving memory.
To ensure that the improvement observed in mice treated with
P7C3-S243 in this assay of learning and memory did not simply
reflect an acceleration of what would otherwise be a normalports 8, 1731–1740, September 25, 2014 ª2014 The Authors 1733
Figure 2. P7C3-S243 Preserves Hippocampal Synaptic Transmission after Blast-Mediated TBI
Treatment with P7C3-S243 rescued blast-injury-induced deficits in long-term potentiation (LTP) and paired-pulse facilitation (PPF) in the hippocampal CA1
Schaffer-collateral pathway.
(A) LTP induced by 12 theta burst stimulation (TBS) is significantly decreased in animals that sustained blast-induced TBI 14 days prior to testing.
(B–D) This deficit was not rescued by treatment with (B) low-dose P7C3-S243 (0.3 mg/kg/day) starting 24 hr after injury but was rescued by treatment with higher
doses of (C) 3 and (D) 30 mg/kg/day P7C3-S243.
(E) LTP 1 hr after 12 TBS is summarized by quantification of the initial slope.
(F) Blast-injury-induced PPF deficit of 50ms interpulse interval was also rescued in animals treatedwith the two higher doses (3 and 30mg/kg/day) of P7C3-S243.
Data are represented as mean ± SEM. Statistics were determined by one-way ANOVA with Tukey’s post hoc test.recovery response after injury, we compared performance of
sham- versus blast-injured mice 8 months after a single blast
injury. As shown in Figures S2S–S2U, equivalent deficits in
learning and all three measures of memory in the Barnes maze
are noted in untreated animals at this chronic time point. Future
experiments in our laboratory will determine whether P7C3-S243
or related agents offer protection from the chronic conse-
quences of blast-mediated TBI as well.
P7C3-S243 Preserves Hippocampal Synaptic Function
after Blast-Mediated TBI
To test our hypothesis that preserved performance in the Barnes
maze was associated with hippocampal function, we investi-
gated synaptic plasticity in the hippocampus. Specifically, we
measured both long-term potentiation (LTP) and paired pulse
facilitation (PPF) in brain slices derived from mice exposed to1734 Cell Reports 8, 1731–1740, September 25, 2014 ª2014 The Aublast injury as a function of treatment with different doses of
P7C3-S243 for 9 days, initiated 24 hr after injury, in animals not
subjected to behavioral testing. The stimulating electrode acti-
vated CA3 Schaeffer collateral axons, and the recording elec-
trode was placed in the stratum radiatum of the CA1 region,
where Schaffer collateral axons synapse with dendrites from
CA1 pyramidal cells. As shown in Figure 2, blast injury induced
significant deficits in both measures, and low-dose (0.3 mg/kg/
day) P7C3-S243 had no effect. This dose also did not preserve
memory in the Barnes maze probe test (Figure 1). However,
treatment with higher doses (3 and 30 mg/kg/day) of P7C3-
S243, which did preserve normal memory after injury (Figure 1),
preserved both LTP and PPF in the hippocampus (Figure 2).
Thus, dose-dependent protective efficacy of P7C3-S243 in
behavioral tasks of learning and memory correlated with hippo-
campal function.thors
Figure 3. P7C3-S243 Blocks Axonal Degen-
eration after Blast-Mediated TBI
(A) Representative pictures from CA1 stratum ra-
diatum show prominent silver staining of degen-
erating axons 12 days after blast injury, in the
absence of loss of NeuN of hematoxylin and eosin
(H&E) staining. Images shown are representative
of typical images from five animals in each group
and demonstrate that 3 and 30 mg/kg/day doses
of P7C3-S243, initiated 24 hr after blast injury,
block axonal degeneration. Similar protective ef-
ficacy is seen in animals treated with 3 mg/kg/day
of the highly active enantiomer ()-P7C3-S243,
but not in animals treated with the less-active
enantiomer (+)-P7C3-S243 (scale bar represents
2.5 mM).
(B) Optical densitometry of light transmitted
through silver-stained CA1 stratum radiatum from
all animals in each group was used to quantify the
protective effect. Signal was quantified for 18
sections for each of the five animals, spaced
480 mM apart. A greater value indicates that more
light passed unimpeded through the section by
virtue of less silver staining, which reflects less
axonal degeneration. Data are represented as
mean ± SEM. *p < 0.05 was determined by two-
way ANOVA with Bonferroni post hoc analysis.
See also Figure S3.P7C3-S243 Blocks Axonal Degeneration after Blast-
Mediated TBI
Histologic examination of brain tissue 12 days after blast injury
revealed prominent axonal degeneration in the absence of cell
death or acute inflammation. As shown in Figure 3A, silver stain-
ing of degenerating axons was markedly increased in the CA1
stratum radiatum, without loss of cell bodies in the dentate gyrus.
Automated optical densitometry of silver-stained tissue was
used to quantify the magnitude of staining, such that greater
impedance of light through the section reflected greater axonal
degeneration (Figure 3B). Given that we report an automated
and unbiased objective method of quantification, we verified
that the results correlated with a previously established method
of quantifying silver staining through manually delineating the
area of interest and determining optical density of silver staining
on the same section through NIH Image J software (Northington
et al., 2001). Figure S3A shows that our automated method
correlated perfectly with this previously established method.
Our analysis showed that degeneration of axons was blocked
by treatment with P7C3-S243 at doses of 3 and 30 mg/kg/day
when initiated 24 hr after injury. Treatment with 3 mg/kg/day of
()-P7C3-S243 also offered significant protection from axonal
degeneration, whereas the same dose of the less-active enan-
tiomer (+)-P7C3-S243 did not. Similar protective efficacy of 3
and 30 mg/kg/day of P7C3-S243 was also observed outsideCell Reports 8, 1731–1740, Septhe hippocampus, including corpus cal-
losum, thalamus, cortex, olfactory bulb,
striatum, and cerebellum (Figures S3B–
S3D). Again, axonal degeneration in
these regions preceded frank neuronal
cell death (Figures S3E and S3F) or deathof other cell types (Figures S3G and S3H). P7C3-S243 is likely
acting directly on neurons to block axonal degeneration, as we
have previously shown that P7C3 does not affect oligodendro-
cytes (Pieper et al., 2010).
As neurodegenerative processes can be associated with neu-
roinflammation, we examined glial fibrillary acidic protein (GFAP)
staining. Somewhat surprisingly, we did not observe elevated
GFAP after blast injury (Figure S3I). As immunohistochemical
staining was conducted 12 days after injury, we looked earlier
for changes in relative gene expression in the inflammatory inter-
leukin-1 (IL-1) pathway, which has been suggested to be active
in some mouse models of TBI (Lloyd et al., 2008; Clausen
et al., 2009). We examined IL-1 pathway expression in the hippo-
campus 2 and 24 hr after blast injury and saw no meaningful
changes (Tables S1 and S2). Our data thus show that wide-
spread axonal damage and degeneration, in the absence of
acute inflammation or widespread cell death, is the predominant
neuropathologic feature in the brains of mice in our model of
blast-mediated TBI at these early time points. This finding is
reflective of the pathology observed in humans with mild TBI.
To further examine hippocampal structural pathology, we next
turned to ultrathin (1 mM) section histology using toluidine blue
staining, as well as transmission electron microscopy (TEM) (Fig-
ure S4A). As shown in Figure 4, sham-injury mice treated with
vehicle displayed densely packed pyramidal neurons in CA1tember 25, 2014 ª2014 The Authors 1735
Figure 4. Toluidine Blue Staining and Trans-
mission Electron Microscopy Visualization
of Hippocampal Protection byOrally Admin-
istered ()-P7C3-S243 after Blast Injury
Daily oral administration of the highly active
enantiomer ()-P7C3-S243 for 14 days, starting
24 hr after injury, dose-dependently preserved
CA1 morphology as well as myelin and mito-
chondrial structures in the hippocampus after
blast injury. Two weeks after either sham or blast
injury, animals were perfused and processed for
ultrastructural pathology. Toluidine-blue-stained
semithin sections (left panel) of sham-injured mice
treated with vehicle or ()-P7C3-S243 showed
normal CA1 histology, with densely packed neu-
rons in the stratum pyramidale (1) and profuse
dendritic profiles in the stratus radiatum (2; black
arrows). Blast-injured animals treated with vehicle
showed accumulation of chromatolytic and py-
knotic neurons (white arrow) throughout the stra-
tum pyramidale as well as fewer dendrites in
the stratum radiatum. There is no protection in
CA1 morphology at the lowest concentration of
blast-injured animals treated with 0.3 mg/kg/day
of ()-P7C3-S243. However, treatment with
3 mg/kg/day ()-P7C3-S243 lowered the abun-
dance of chromatolytic and pyknotic neurons and
resulted in a more densely packed stratum
pyramidale. At the highest concentration (30 mg/
kg/day) of ()-P7C3-S243, there was complete
preservation of CA1 morphology after blast-
mediated TBI. Transmission electron micrographs
(TEM) (right panel) of immediately adjacent ultra-
thin sections showed normal myelin and axonal
mitochondrial structures in the stratum radiatum of
sham-injurymice treatedwith vehicle or ()-P7C3-
S243. Blast-injured mice treated with vehicle or
0.3 mg/kg/day of ()-P7C3-S243 showed degen-
eration of myelin sheath (red arrows), along with
abnormal outer membrane and internal cristae
structures within neuronal mitochondria (blue
arrows). At 3 and 30 mg/kg/day doses, however,
both myelin and neuronal mitochondria were pre-
served. Pictures shown are representative of four
animals per condition. The scale bars represent
50 mM in Toluidine blue and 500 nm in TEM. See
also Figure S4.stratum pyramidale, with abundant dendritic extensions into the
stratum radiatum. These parameters did not change in sham-
injured mice treated with orally administered ()-P7C3-S243
(30 mg/kg/day). In blast-injured animals, however, we observed
accumulation of chromatolytic and pyknotic neurons in the1736 Cell Reports 8, 1731–1740, September 25, 2014 ª2014 The AuthorsCA1 stratum pyramidale, accompanied
by decreased dendritic extensions in
the stratum radiatum. These changes
indicate general ongoing pathologic pro-
cesses associated with neurodegenera-
tion preceding neuronal cell death and
are consistent with our electrophysiologic
data in Figure 2. In blast-injured animals
treated with low-dose (0.3 mg/kg/day)oral ()-P7C3-S243, these same pathologic features were pre-
sent (Figure 4). Initiation of treatment 24 hr after injury with an in-
termediate dose (3 mg/kg/day) of oral ()-P7C3-S243, however,
appeared to decrease the abundance of pyknotic pathology
in the CA1 stratum pyramidale and partially preserve dendritic
Figure 5. P7C3-S243 Blocks Cerebellar
Axonal Degeneration and Preserves Bal-
ance and Coordination
(A) Representative pictures from the cerebellar
molecular layer show prominent silver staining of
degenerating axons 12 days after blast injury, in
the absence of loss of NeuN or H&E staining. Im-
ages shown are representative of typical images
from five animals in each group and demonstrate
that 3 and 30 mg/kg/day doses of P7C3-S243,
initiated 24 hr after blast injury, block axonal
degeneration. Similar protective efficacy is seen in
animals treated with 3 mg/kg/day of the highly
active enantiomer ()-P7C3-S243, but not in ani-
mals treated with the less-active enantiomer
(+)-P7C3-S243. The scale bar represents 2.5 mM.
(B) Optical densitometry of light transmitted
through silver-stained cerebellar molecular layer
from all animals in each group was used to
quantify the protective effect. The specific tissue
area was manually delineated, and signal was
quantified for 18 sections for each of the five ani-
mals, spaced 480 mM apart. A greater value in-
dicates that more light passed unimpeded through
the section by virtue of less silver staining, which
reflects less axonal degeneration.
(C) Seven days after blast injury, mice show a trend
toward impaired balance and coordination with
increased foot slips that did not achieve statistical
significance. By 28 days, however, blast-injured
mice showed a 2-fold increase in the number of
foot slips relative to sham-injured mice. When
daily oral treatment with 6 mg/kg/day of the active
enantiomer ()-P7C3-S243 was initiated 24 hr
after blast injury, however, mice performed nor-
mally in this task. Every group shown consisted of
25 male C57/Bl6 mice, aged 12–14 weeks, and
data were collected and scored in an automated
manner blind to treatment group. Significance was
determined by two-way ANOVA with Bonferroni
post hoc analysis. Data are represented as mean
± SEM. **p < 0.01 and ****p < 0.0001 compared to
blast-injured animals treated with vehicle.
See also Figures S5 and S6.extension into the stratum radiatum in blast-injured mice. A
higher dose (30 mg/kg/day) of oral ()-P7C3-S243 fully pre-
served all structural aspects of this region in blast-injured mice.
The stratum radiatum is where CA3 Schaeffer collateral axons
synapse with dendrites of CA1 pyramidal cells. This was the cir-
cuit we investigated electrophysiologically (Figure 2), and we
next turned to TEM to further characterize blast-injury-induced
axonal degeneration. As shown in Figure 4, we observed nor-
mally myelinated axons in the stratum radiatum of sham-injury
mice treated with vehicle or orally administered ()-P7C3-S243
(30 mg/kg/day). These axons contained intact and healthy-ap-
pearing mitochondria. In blast-injured animals treated with
vehicle or low-dose (0.3 mg/kg/day) oral ()-P7C3-S243, how-
ever, we observed degenerating axons with characteristic un-
raveling of the myelin sheath. In addition, neuronal mitochondriaCell Recontained within these degenerating axons showed both
swelling and degenerating outer membrane and internal cristae.
Initiation of treatment 24 hr after injury with an intermediate dose
(3 mg/kg/day) of oral ()-P7C3-S243 achieved partial resolution
of pathological signs in both axons and neuronal mitochondria,
and treatment with the higher oral dose (30 mg/kg/day) achieved
full protection (Figure 4). To illustrate the robust effect, additional
representative figures from each group are shown in Figure S4.
P7C3-S243 Preserves Cerebellar Function and Axonal
Integrity after Blast-Mediated TBI
Extensive axonal degeneration was also observed in the molec-
ular layer of the cerebellum in blast-injured mice treated with
vehicle or low-dose (0.3 mg/kg/day) P7C3-S243, again in the
absence of cell death (Figures 5A and 5B). As in other brainports 8, 1731–1740, September 25, 2014 ª2014 The Authors 1737
regions, axonal degeneration was blocked in the molecular layer
by treatment with 3 and 30 mg/kg/day P7C3-S243, as well as
3 mg/kg/day of the highly active enantiomer ()-P7C3-S243,
but not by treatment with the same dose of the less-active
enantiomer (+)-P7C3-S243 (Figures 5A and 5B). Because the
cerebellum controls coordination, we next assayed balance
and coordination, using standard procedures (Luong et al.,
2011). Mice were trained to cross an 80 cm long beam over
2 days and then sham or blast injured on day 3. Daily oral admin-
istration of ()-P7C3-S243 was initiated 24 hr later, and animals
were tested 7 and 28 days after injury. Mice were videotaped
during the test and then analyzed for the number of foot slips
by observers blind to treatment group. Seven days after blast
injury, mice showed a trend toward increased number of foot
slips, which did not reach statistical significance. By 28 days
after injury, however, blast-injured mice displayed a 2-fold in-
crease in number of foot slips. This behavioral deficit was
normalized by daily oral treatment with ()-P7C3-S243, initiated
24 hr after injury. Thus, protective efficacy for cerebellar axonal
degeneration after injury by ()-P7C3-S243 correlated with pres-
ervation of motor coordination.
As with cognitive measures, we verified that the protective
effect of treatment with P7C3-S243 did not simply reflect an ac-
celeration of what might otherwise be a normal recovery process
after injury. As shown in Figure S5, 8 months after a single blast
injury, untreated mice continue to show a statistically significant
deficit in ability to perform this task of motor coordination.
Acquisition of Anxiety-like Phenotypes Chronically after
Blast-Mediated TBI
We additionally analyzed mice at acute and chronic time points
in the Laboras system, which allows 24 hr automated collection
of normal home cage behavior using a vibration-sensitive plate
to monitor motor activity (Xu et al., 2013). Here, we noted acqui-
sition of anxiety-related phenotypes at the chronic time point
that were not observed acutely after injury. Specifically, we
observed increased grooming (Figure S6A) and increased loco-
motion and rearing (Figure S6B) in untreatedmice 8months after
a single blast injury. This phenotype correlates with increased
susceptibility of humans to psychiatric symptoms after TBI.
Future work will focus on expanding this finding, including deter-
mination of whether acute or chronic treatment with P7C3 mole-
cules offer protection from this aspect of TBI as well.
DISCUSSION
Here, we show that the P7C3 class of neuroprotective chemicals
blocks axonal degeneration prior to neuron cell death. Briefly,
administration of P7C3-S243, initiated 24 hr after blast-mediated
TBI, potently preserves axonal integrity throughout the brain.
This axonal rescue is associated with preservation of related
measures of synaptic transmission, hippocampal-dependent
learning and memory, and motor coordination. Examination of
injured mice at chronic time points shows that these behavioral
deficits do not resolve on their own in mice that received only
vehicle and also that injured animals additionally attain behav-
ioral phenotypes related to anxiety at this chronic time point after
injury. We propose that P7C3-S243 serves as a chemical scaf-1738 Cell Reports 8, 1731–1740, September 25, 2014 ª2014 The Aufold upon which new drugs can be designed to treat patients
with conditions of axonal degradation, such as occurs in TBI or
other neurodegenerative diseases. Such an agent would have
broad applicability, as axon degeneration proceeds through
unique mechanisms distinct from cell death (Yan et al., 2010),
and most forms of neurodegenerative disease involve degrada-
tion of synapses and axons preceding loss of neuronal cell
bodies (Li et al., 2001; Raff et al., 2002; Coleman and Yao,
2003; Fischer et al., 2004; Gunawardena and Goldstein, 2005;
Luo and O’Leary, 2005).
Howmight P7C3-S243 act to protect axons? In the accompa-
nying manuscript (Wang et al., 2014), we show that active P7C3
variants bind and enhance activity of the enzyme nicotinamide
phosphoribosyltransferase (NAMPT). NAMPT synthesizes nico-
tinamide mononucleotide (NMN) from nicotinamide, the rate-
limiting step in nicotinamide adenine dinucleotide (NAD) salvage
(Preiss and Handler, 1958), and NAD is known to play a vital role
in axon degeneration. For example, the Wallerian degeneration
slow strain of mice is resistant to axonal degeneration after injury
(Lunn et al., 1989) by virtue of a triplicated fusion gene, resulting
in overexpression of nicotinamide mononucleotide adenylyl-
transferase 1 (Araki et al., 2004), the enzyme that converts
NMN into NAD. Furthermore, it has also been shown that treat-
ment with NAD and NAD precursors, including nicotinamide,
nicotinic acid mononucleotide, and NMN, or overexpression of
NAMPT achieves axonal protection in vitro (Araki et al., 2004; Sa-
saki et al., 2006;Wang et al., 2005). Thus, active variants of P7C3
may protect from axonal degeneration by enhancing intracellular
production of NAD through enhancing NAMPT activity. In
conclusion, it is our hope that the P7C3 family of neuroprotective
chemicals will form the basis for a new class of therapeutics
applicable to a variety of conditions of nerve cell dysfunction
currently lacking treatment options.
EXPERIMENTAL PROCEDURES
Animals
Approval for animal experiments was obtained from the University of Iowa
Institutional Animal Care and Use Committee. Mice were singly housed in
the University of Iowa vivarium in a temperature-controlled environment with
lights on 0600–1800. Mice had ad libitum access to water and standard
chow. Eight-week-old C57BL6 wild-type mice were obtained from Jackson
Laboratories.
Blast-Mediated Traumatic Brain Injury
Mice were anesthetized with ketamine/xylazine (1 mg/kg and 0.1 mg/kg,
respectively) and placed in an enclosed blast chamber (50 cm long and
33 cm wide) constructed from an air tank partitioned into two sides. One
sidewas pressurizedwith a 13 cmopening between the partitions and covered
with a mylar membrane. The unpressurized partition contained a restraint
10 cm from the mylar membrane, into which the mouse was placed. The
head was freely moving whereas a metal tube shielded the body. Compressed
air was forced into the pressurized partition until the mylar membrane burst at
22 kPa. The blast wave impacted the test animal inside a foam-lined restraint
to reduce blunt impact trauma of the head against the metal tube. The left side
of the head was closest the origin of the blast wave. Sham-injured animals
were anesthetized in the same way and not subjected to the blast.
P7C3 Series of Compounds Formulation
Compound formulation was conducted using previously described methods
(Pieper et al., 2010, Naidoo et al., 2014).thors
Statistics
GraphPad Prism 6 software was used to perform all statistical analyses.
For detailed methodology of blood-brain barrier studies, Barnes maze,
immunohistochemistry, electron microscopy, and electrophysiology studies,
IL-1 pathway analysis, foot slip assay, and LABORAS assay, see Supple-
mental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.08.030.
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